Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Large Growth in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 221,900 shares, an increase of 14.3% from the March 15th total of 194,200 shares. Based on an average daily volume of 224,000 shares, the short-interest ratio is presently 1.0 days. Approximately 1.9% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CMMB. Roth Capital reaffirmed a “buy” rating on shares of Chemomab Therapeutics in a research report on Tuesday, December 19th. Roth Mkm reaffirmed a “buy” rating and set a $7.00 price target on shares of Chemomab Therapeutics in a research report on Tuesday, December 19th.

Chemomab Therapeutics Stock Down 9.5 %

NASDAQ CMMB traded down $0.07 on Tuesday, reaching $0.66. The stock had a trading volume of 37,664 shares, compared to its average volume of 207,249. The firm has a market capitalization of $7.30 million, a price-to-earnings ratio of -0.31 and a beta of 0.36. Chemomab Therapeutics has a 12-month low of $0.42 and a 12-month high of $1.89. The stock has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $0.66.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its earnings results on Thursday, March 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14. During the same period in the previous year, the business posted ($0.72) earnings per share. Sell-side analysts forecast that Chemomab Therapeutics will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Chemomab Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. purchased a new stake in shares of Chemomab Therapeutics during the first quarter worth $52,000. Citadel Advisors LLC purchased a new stake in shares of Chemomab Therapeutics during the third quarter worth $53,000. Renaissance Technologies LLC purchased a new stake in shares of Chemomab Therapeutics during the first quarter worth $134,000. Two Sigma Investments LP purchased a new stake in shares of Chemomab Therapeutics during the first quarter worth $48,000. Finally, Boothbay Fund Management LLC increased its position in shares of Chemomab Therapeutics by 38.1% during the fourth quarter. Boothbay Fund Management LLC now owns 51,608 shares of the company’s stock worth $165,000 after acquiring an additional 14,237 shares during the period. Hedge funds and other institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).